More results...

More results...

MSK-ACCESS® powered with SOPHiA DDM™

Rise above the noise to see what truly matters

pink dots icon

Elevate your precision oncology program.

Push the boundaries of your in-house liquid biopsy capabilities with MSK-ACCESS® powered with SOPHiA DDM™, a decentralized version of the rigorously validated cell-free DNA (cfDNA) assay developed and used in clinical routine by Memorial Sloan Kettering Cancer Center (MSK)1,2.

Discover an innovative solution that combines MSK’s expertise in cancer genomics with the robust analytics of the SOPHiA DDM™ Platform for paradigm-shifting liquid biopsy insights.

Contact us

Clinical knowledge-driven design

Focus on what matters with a comprehensive 146 gene panel curated by MSK experts.

End-to-end application

Save time with a streamlined workflow, taking you from cfDNA sample to report in ∼5 days.

Matched tumor-normal approach

Reduce noise by filtering clonal hematopoiesis of indeterminate potential (CHIP) and germline variants.

Robust analytical performance

Trust your results with demonstrated 99.4% positive percent agreement (≥0.5% VAF) to MSK-ACCESS® used at MSK3.

Tumor-informed variant calling

Maximize insights with informed variant calling across sequential tests, facilitating longitudinal monitoring.

Integrated analysis and reporting

Increase efficiency with the robust analytics and user-friendly interpretation and reporting features of SOPHiA DDM™.

pink dots icon

Save time with a streamlined end-to-end workflow

Equip your laboratory with a true sample-to-report workflow that combines in-house hybrid capture and cloud-based analytics, allowing you to to retain ownership of your samples and data.

Easy library preparation and capture

146 gene panel focused on actionability, curated by MSK experts and selected from MSK’s cancer genomic profiling assay, MSK-IMPACT®

Hybridization-based capture with deep sequencing (~20,000x)

Tailored probes for high on-target rate and coverage uniformity

Minimal input amount of only 20 ng cfDNA

Ready-to-sequence libraries in just 1.5 days

Optimized multiplexing of paired tumor-normal samples for a cost-effective process

Compatible with NovaSeq™ 6000 and NextSeq® 2000 sequencers

    Advanced analysis with the SOPHiA DDM™ Platform

    Algorithm-powered detection of SNVs, Indels, CNV, and fusions

    Proprietary unique molecular identifier (UMI) technology, CUMIN™, for sensitive variant detection down to 0.5% VAF

    Tumor-informed variant calling to facilitate follow-ups and decision-making

    Tertiary analysis based on the latest scientific evidence on relevant variants with OncoPortal™ Plus​

    Access to MSK’s Precision Oncology Knowledge Base, OncoKB™, via link-out at gene level for enhanced interpretation support

    Knowledge-sharing within SOPHiA GENETICS Community, one of the largest networks of connected healthcare institutions

    What is CHIP?

    Somatic mutations accumulate in cells with a hematopoietic lineage (e.g. stem cells in the bone marrow) as we age or in response to environmental influences. These mutations are known as CHIP. CHIP mutations can be detected in the plasma and wrongly attributed to solid tumor origins4,5.

    Learn more about CHIP

    Reduce noise with a matched tumor-normal approach

    Clonal hematopoiesis of indeterminate potential (CHIP) is a common cause of biological false positives in cfDNA analysis4. MSK-ACCESS® powered with SOPHiA DDM™ leverages a matched tumor-normal approach that enables CHIP filtering and eliminates the risk of:

    • Biological false positives at low allele frequencies (e.g. in BRCA1).
    • Removing true positives, if using only database-driven approaches to annotate CHIP2.

    By sequencing tumor-derived cfDNA and normal white blood cell DNA in parallel, you can effectively reduce noise in your data analysis and focus on tumor-specific somatic variants.

      Trust your data

      Exceptional analytical performance3

      In an end-to-end comparison of 48 clinical cfDNA + matched white blood cell DNA samples, MSK-ACCESS® powered with SOPHiA DDM™ achieved 99.4% positive percent agreement (≥0.5% VAF) with the centralized version used at MSK.

      PPA, positive percent agreement; VAF, variant allele frequency. a Based on end-to-end concordance analysis between MSK-ACCESS® powered with SOPHiA DDM™ and centralized version of MSK-ACCESS® at MSK, using 48 clinical cfDNA + matched WBC DNA samples; b Correlation of variant allele fraction to reference method.

        Searching for robust insights? Let SOPHiA DDM™ search for you

        The trusted analytics and advanced features of the SOPHiA DDM™ Platform enable the accurate detection and characterization of complex genomic variants, while adhering to the most up-to-date international guidelines.

        OncoPortal™ Plus further supports decision-making and reporting by matching tumor molecular profiles with clinical associations and available clinical trials. In addition to an integrated workflow leveraging on JAX-CKB™, you can access MSK’s Precision Oncology Knowledge Base, OncoKB™, via a link in SOPHiA DDM™ for comprehensive genomic insights.

        REQUEST A FULL DEMO

        Addressing global inequalities in comprehensive cancer care

        AstraZeneca and MSK have joined forces with SOPHiA GENETICS to revolutionize cancer research. Together, we are creating a decentralized global network for liquid biopsy testing, including underserved regions where access remains scarce. 

        Generating an unparalleled and comprehensive dataset sourced from diverse populations holds the potential for invaluable insights that could shape the future of global healthcare.

        READ PRESS RELEASE

        Specifications

        Content
        		 146 genes
        Diseases Covered
        		 Multi-cancer (any solid tumor)
        Detected Variants
        		 • SNVs and Indels in 146 genes
        • CNVs in 71 genes
        • Fusions (DNA-based via intronic targets) in 10 genes
        • TERT promoter
        Sample Type
        		 Paired samples of cell-free DNA extracted from peripheral blood and white blood cell gDNA
        Starting Material
        		 20 ng cell-free DNA (minimum); 50 ng white blood cell (WBC) gDNA (minimum)
        Recommended Read Length
        		 150 bp, paired end
        Coverage Depth
        		 Approx. 20,000x
        Multiplexing (samples per run)
        		 Illumina NovaSeq™ 6000:
        • SP flow cell: 8 (tumor + normal) pairs
        • S1 flow cell: 16 (tumor + normal) pairs
        • S2 flow cell: 40 (tumor + normal) pairs
        • S4 flow cell: 96 (tumor + normal) pairs

        Illumina NextSeq® 2000 (P3 flow cell):
        • 8 (tumor + normal) pairs, with 33% sequencing space left
        Library Preparation Time
        		 1.5 days
        pink dots icon

        Want to know more?
        Get in touch with us.

        Our client services team is on hand to help.

        References

        1. MSK. MSK-ACCESS®. Available at: https://www.mskcc.org/departments/division-solid-tumor-oncology/early-drug-development-service-phaseclinical-trials/precision-medicine-approach/msk-access (Accessed April 2024). 
        2. Brannon AR, et al. Nat Commun. 2021;12(1):3770. 
        3. Data on File.
        4. Pascual J, et al. Ann Oncol. 2022;33(8):750-768.
        5. Lockwood CM, et al. J Mol Diagn. 2023;25(12):876-897.

         

        ';